Despite progress in targeting epidermal growth factor receptor-mutant (EGFRm) non-small cell lung cancer (NSCLC), acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is inevitable. This evidence concerns the gene EGFR and non-small cell lung carcinoma.